Patents by Inventor Frank W. Rasmussen

Frank W. Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VARIANTS AND COMPOSITIONS COMPRISING VARIANTS WITH HIGH STABILITY IN PRESENCE OF A CHELATING AGENT
    Publication number: 20230002748
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Application
    Filed: August 22, 2022
    Publication date: January 5, 2023
    Applicant: Novozymes A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • Variants and compositions comprising variants with high stability in presence of a chelating agent
    Patent number: 11453868
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: September 27, 2022
    Assignee: NOVOZYMES A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • Protease variants and polynucleotides encoding same
    Patent number: 11198860
    Abstract: The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 14, 2021
    Assignee: NOVOZYMES A/S
    Inventors: Frank W. Rasmussen, Miguel Duarte Guilherme Pereira Toscano, Lars L. H. Christensen, Esben Peter Friis
  • VARIANTS AND COMPOSITIONS COMPRISING VARIANTS WITH HIGH STABILITY IN PRESENCE OF A CHELATING AGENT
    Publication number: 20210317431
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Application
    Filed: March 17, 2021
    Publication date: October 14, 2021
    Applicant: NOVOZYMES A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • VARIANTS AND COMPOSITIONS COMPRISING VARIANTS WITH HIGH STABILITY IN PRESENCE OF A CHELATING AGENT
    Publication number: 20200270593
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Application
    Filed: March 30, 2020
    Publication date: August 27, 2020
    Applicant: NOVOZYMES A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • Variants and compositions comprising variants with high stability in presence of a chelating agent
    Patent number: 10655116
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 19, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • VARIANTS AND COMPOSITIONS COMPRISING VARIANTS WITH HIGH STABILITY IN PRESENCE OF A CHELATING AGENT
    Publication number: 20190359961
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Application
    Filed: March 25, 2019
    Publication date: November 28, 2019
    Applicant: NOVOZYMES A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • Protease variants and polynucleotides encoding same
    Patent number: 10400230
    Abstract: The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: September 3, 2019
    Assignee: NOVOZYMES A/S
    Inventors: Frank W. Rasmussen, Miguel Duarte Guilherme Pereira Toscano, Lars L. H. Christensen, Esben Peter Friis
  • Variants and compositions comprising variants with high stability in presence of a chelating agent
    Patent number: 10240135
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 26, 2019
    Assignee: NOVOZYMES A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • PROTEASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME
    Publication number: 20180355338
    Abstract: The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 13, 2018
    Applicant: NOVOZYMES A/S
    Inventors: Frank W. Rasmussen, Miguel Duarte Guilherme Pereira Toscano, Lars L.H. Christensen, Esben Peter Friis
  • Compositions of high stability alpha amylase variants
    Patent number: 9896673
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: February 20, 2018
    Assignee: Novozymes A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • VARIANTS AND COMPOSITIONS COMPRISING VARIANTS WITH HIGH STABILITY IN PRESENCE OF A CHELATING AGENT
    Publication number: 20180010111
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 11, 2018
    Applicant: NOVOZYMES A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • PROTEASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME
    Publication number: 20170349890
    Abstract: The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 7, 2017
    Applicant: NOVOZYMES A/S
    Inventors: Frank W. Rasmussen, Miguel Duarte Guilherme Pereira Toscano, Lars L.H. Christensen, Esben Peter Friis
  • POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION
    Publication number: 20160229883
    Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5?-(Gx)TxTxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.
    Type: Application
    Filed: March 27, 2013
    Publication date: August 11, 2016
    Inventors: Majken Westergaard, Charlott A. Thrue, Henrik F. Hansen, Frank W. Rasmussen
  • POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION
    Publication number: 20140294897
    Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5?-(Gx)TxTxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.
    Type: Application
    Filed: March 27, 2013
    Publication date: October 2, 2014
    Inventors: Majken Westergaard, Charlott A. Thrue, Henrik F. Hansen, Frank W. Rasmussen
  • Variants And Compositions Comprising Variants With High Stability In Presence Of A Chelating Agent
    Publication number: 20110195481
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Application
    Filed: February 10, 2011
    Publication date: August 11, 2011
    Applicant: Novozymes A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION
    Publication number: 20110183931
    Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5?-(Gx)TxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.
    Type: Application
    Filed: April 4, 2011
    Publication date: July 28, 2011
    Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventors: Majken Westergaard, Charlotte A. Thrue, Frank W. Rasmussen, Henrik F. Hansen
  • POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1a EXPRESSION
    Publication number: 20090286859
    Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5-(Gx)TxTxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.
    Type: Application
    Filed: June 3, 2009
    Publication date: November 19, 2009
    Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventors: Majken Westergaard, Charlotte A. Thrue, Frank W. Rasmussen, Henrik F. Hansen
  • Potent LNA oligonucleotides for the inhibition of HIF-1A expression
    Patent number: 7589190
    Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5?-(Gx)TxTxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: September 15, 2009
    Assignees: Santaris Pharma A/S
    Inventors: Majken Westergaard, Charlotte A. Thrue, Frank W. Rasmussen, Henrik F. Hansen
  • Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
    Patent number: 5622988
    Abstract: The present invention relates to the use of compounds of formula I ##STR1## wherein R.sup.1 is independently hydrogen, hydroxy, alkyl with 1 to 6 carbon atoms, acyloxy groups with 1 to 6 carbon atoms, alkyloxy with 1 to 6 carbon atoms or from 1 to 5 sugar moieties; and R.sup.2 is independently hydrogen, or alkyl with 1 to 6 carbon atoms, in the reduction of coagulation time in mammals.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: April 22, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Helle Worsaae, Frank W. Rasmussen, Mirella E. Rasmussen